Brief: Opregen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit
06/05/2024 13:09
May 6 (Reuters) - Lineage Cell Therapeutics Inc
LCTX.A :
* OPREGEN® (RG6501) PHASE 1/2A CLINICAL STUDY 24-MONTH
VISUAL
ACUITY RESULTS FEATURED AT 2024 RETINAL CELL & GENE THERAPY
INNOVATION SUMMIT
Source text for Eikon: ID:nBw52FxKDa
Further company coverage: LCTX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lineage Cell Therapeutics
See all newsLineage Cell Therapeutics Q2 revenue falls but posts profit
Brief: Lineage Cell Therapeutics Q2 Income From Operations USD -8.923 Million
Lineage Cell Therapeutics Q1 net loss widens as expenses rise
Lineage Cell Q4 revenue rises on Genentech collaboration
Brief: Lineage Cell Therapeutics FY Income From Operations USD -36.619 Million